Corpus Intelligence IC Memo — TEMPLE UNIVERSITY HOSPITAL 2026-04-26 06:40 UTC
IC Memo — TEMPLE UNIVERSITY HOSPITAL
Investment Committee Memorandum | PA | 761 beds | Grade C | EBITDA uplift $146.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TEMPLE UNIVERSITY HOSPITAL

CCN 390027 | PHILADELPHIA, PA | 761 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

TEMPLE UNIVERSITY HOSPITAL is a 761-bed large academic medical center in PHILADELPHIA, PA with $1.99B in net patient revenue and a 0.8% operating margin. The hospital serves a payer mix of 16.7% Medicare, 5.5% Medicaid, and 77.9% commercial.

Thesis: Undervalued. Our ML models identify $146.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.8% to 8.1% (+736bps).

Net Revenue HCRIS$1.99B
Current EBITDA COMPUTED$15.6M
Operating Margin COMPUTED0.8%
Occupancy HCRIS71.4%
Revenue / Bed COMPUTED$2.6M
Net-to-Gross HCRIS13.3%
Distress Probability ML41.4%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
18
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 0.8% places it above the state median. Among 18 size-comparable peers (380-1522 beds), the median margin is -7.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (380-1522), prioritizing same-state peers. 18 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TEMPLE UNIVERSITY HOSPITAL (Target)PA761$1.99B0.8%
ST. LUKES HOSPITALPA633$8.94B87.9%
HOSPITAL OF THE UNIV OF PENNAPA1051$3.36B-12.8%
LEHIGH VALLEYPA1190$2.84B-5.9%
THE CHILDRENS HOSPITAL OF PHILPA667$2.70B-26.8%
UPMC - PRESBYTERIAN SHADYSIDEPA1141$2.24B-23.0%
MILTON S. HERSHEY MEDICAL CENTPA616$2.08B-2.8%
THOMAS JEFFERSON UNIV. HOSPITAPA868$1.93B-23.1%
GEISINGER MEDICAL CENTERPA525$1.58B4.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $146.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$41.7M+210bp18mo
Cost to Collect4.5%2.5%$39.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$39.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$24.2M+122bp9mo
Clean Claim Rate88.0%96.0%$1.3M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$41.7M
Cost to Collect
$39.7M
Denial Rate Reduction
$39.3M
A/R Days Reduction
$24.2M
Clean Claim Rate
$1.3M
Total EBITDA Uplift$146.2M
Current EBITDA$15.6M
+ RCM Uplift+$146.2M
Pro Forma EBITDA$161.8M
Current Margin0.8%
Pro Forma Margin8.1%
WC Released (1x)$76.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$24.0M$1.56B65.08x130.5%
Base (11x exit)10.0x11.0x$24.0M$1.73B71.92x135.2%
Bull Case9.0x11.0x$21.6M$2.22B102.56x152.5%
Bull (12x exit)9.0x12.0x$21.6M$2.43B112.18x157.0%
Bear Case11.0x10.0x$26.4M$826.1M31.24x99.0%
Bear (11x exit)11.0x11.0x$26.4M$917.2M34.69x103.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 18 hospitals with 380-1522 beds
  • Same-state prioritization (n=19)
  • Comp margins: P25=-17.8% / P50=-7.4% / P75=3.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.